Tyra Biosciences, Inc. (TYRA)
NASDAQ: TYRA · Real-Time Price · USD
10.25
-0.05 (-0.49%)
May 1, 2025, 12:01 PM EDT - Market open
Tyra Biosciences Employees
Tyra Biosciences had 60 employees as of December 31, 2024. The number of employees increased by 11 or 22.45% compared to the previous year.
Employees
60
Change (1Y)
11
Growth (1Y)
22.45%
Revenue / Employee
n/a
Profits / Employee
-$1,441,350
Market Cap
544.17M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 60 | 11 | 22.45% |
| Dec 31, 2023 | 49 | 11 | 28.95% |
| Dec 31, 2022 | 38 | 13 | 52.00% |
| Dec 31, 2021 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
TYRA News
- 4 weeks ago - Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - PRNewsWire
- 2 months ago - Tyra Biosciences to Present at Upcoming Investor Conferences - PRNewsWire
- 3 months ago - Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium - PRNewsWire
- 3 months ago - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) - PRNewsWire
- 6 months ago - Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - PRNewsWire
- 6 months ago - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PRNewsWire
- 6 months ago - Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga
- 6 months ago - Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PRNewsWire